UNSPSC 51363304: Rogletimide

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 14P4QR28QF, chemically known as 2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)- but generally known as rogletimide, which bears US NIH Compound Identifier 56487. European Medicines Agency schedules Rogletimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10360MIG.

UNSPSC 51363304 Rogletimide, a Commodity code, shows minimal alignment between its nominal pharmaceutical scope and the state and local opportunities recently tagged under it. The three opportunities posted in the block—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's direct-to-manufacturer pharmacy program RFI, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP—address naloxone distribution, pharmacy benefit management infrastructure, and generic OTC product supply chains respectively. None of these solicitations target rogletimide specifically or pharmaceutical products in the therapeutic class the code name suggests. The mismatch indicates either inconsistent code assignment by the issuing bodies or that the code is underutilized for its stated purpose in recent state and local procurement activity.

The issuing-body mix spans county health departments, state HHS commissions, and state-level cooperative purchasing consortia. Seminole County, Florida issued an IFB (due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term; the Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs; and MMCAP, administered by Minnesota's Department of Administration, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon. Geographic activity appears concentrated in Florida, Texas, and Minnesota, with the MMCAP opportunity extending across multiple states through the cooperative purchasing vehicle. The absence of rogletimide-specific opportunities and the breadth of unrelated pharmaceutical procurement suggests this code sees little focused activity in current state and local solicitations.